These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 2447718)
1. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Duggan MA; Masters CB; Alexander F Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718 [TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
4. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions. al-Saffar N; Hasleton PS Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232 [TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
6. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Corson JM; Pinkus GS Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295 [TBL] [Abstract][Full Text] [Related]
7. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects]. Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062 [TBL] [Abstract][Full Text] [Related]
8. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163 [TBL] [Abstract][Full Text] [Related]
9. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. Delahaye M; Hoogsteden HC; Van der Kwast TH J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800 [TBL] [Abstract][Full Text] [Related]
10. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268 [TBL] [Abstract][Full Text] [Related]
11. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. Croonen AM; van der Valk P; Herman CJ; Lindeman J Lab Invest; 1988 Jun; 58(6):725-32. PubMed ID: 3288807 [TBL] [Abstract][Full Text] [Related]
12. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion]. Su XY; Li GD; Liu HB; Jiang LL Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932 [TBL] [Abstract][Full Text] [Related]
13. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Bassarova AV; Nesland JM; Davidson B Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331 [TBL] [Abstract][Full Text] [Related]
14. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Shield PW; Koivurinne K Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry in the diagnosis of malignant mesothelioma. Pfaltz M; Odermatt B; Christen B; Rüttner JR Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887 [TBL] [Abstract][Full Text] [Related]
16. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Ruitenbeek T; Gouw AS; Poppema S Arch Pathol Lab Med; 1994 Mar; 118(3):265-9. PubMed ID: 8135629 [TBL] [Abstract][Full Text] [Related]
17. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302 [TBL] [Abstract][Full Text] [Related]
18. Keratin and carcinoembryonic antigen in exfoliated mesothelial and malignant cells: an immunoperoxidase study. Walts AE; Said JW; Banks-Schlegel S Am J Clin Pathol; 1983 Nov; 80(5):671-6. PubMed ID: 6195913 [TBL] [Abstract][Full Text] [Related]
19. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Zhu W; Michael CW Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661 [TBL] [Abstract][Full Text] [Related]
20. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]